Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients

Key facts

Sponsor

University of Maryland, Baltimore

Principal Investigator

Aldo T Iacono, MD

University of Maryland

Intervention

Liposomal aerosol cyclosporine(drug)

Enrollment

21 enrolled

Eligibility

18 years · All sexes

Timeline

2012 – 2019

Study locations (1)

• University of Maryland Medical Center, Baltimore, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Transplant-related bronchiolitis obliterans

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONNANCT07018804
  Mechanisms and Targeted Therapy of Airway Basal Cell Dysfunction in Bronchiolitis Obliterans Syndrome
  Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
• RECRUITINGPHASE3NCT05654922
  Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant
  Renovion, Inc.
• ACTIVE NOT RECRUITINGPHASE3NCT02181257
  Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts
  Washington University School of Medicine

See all trials for Transplant-related bronchiolitis obliterans →